MedPath

Non-Invasive Chromosomal Evaluation of Trisomy Study

Completed
Conditions
Trisomy 13
Down Syndrome
Aneuploidy
Trisomy 18
Trisomy 21
Registration Number
NCT02201862
Lead Sponsor
Cindy Cisneros
Brief Summary

This study is being conducted to provide clinically annotated samples to support continued improvements in the Ariosa Test content, methodology, specimen processing and quality control.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
2000
Inclusion Criteria
    1. Subject is at least 18 years old and can provide informed consent;
    1. Subject has a viable singleton or twin pregnancy;
    1. Subject is confirmed to be at least 10 weeks, 0 days gestation at the time of the study blood draw;
    1. Subject is planning to undergo CVS and/or amniocentesis for the purpose of genetic analysis of the fetus OR the subject has already undergone CVS and/or amniocentesis and is known to have a fetus with a chromosomal abnormality confirmed by genetic analysis.
Exclusion Criteria
    1. Subject has known aneuploidy;
    1. Subject is pregnant with more than two fetuses or has had sonographic evidence of three or more gestational sacs at any time during pregnancy;
    1. Subject has a fetal demise (including natural or elective reduction) identified prior to consent;
    1. Subject has history of malignancy treated with chemotherapy and/or major surgery, or bone marrow transplant;

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Detection of aneuploidy24 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (3)

Women's Healthcare Group of PA

🇺🇸

Oaks, Pennsylvania, United States

Regional Obestrical Consultants

🇺🇸

Chattanooga, Tennessee, United States

University California San Diego

🇺🇸

San Diego, California, United States

© Copyright 2025. All Rights Reserved by MedPath